Compare Royalty Pharma plc Class A Ordinary Shares (RPRX) vs Global X Uranium ETF (URA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Royalty Pharma plc Class A Ordinary Shares vs Global X Uranium ETF — how do they compare? Royalty Pharma plc Class A Ordinary Shares trades at $56.93 (market cap $25.27B), while Global X Uranium ETF trades at $38.89 (market cap $5.48B). The key difference: Royalty Pharma plc Class A Ordinary Shares is far larger — about 4.6× Global X Uranium ETF's market cap, and Royalty Pharma plc Class A Ordinary Shares pays a 1.66% dividend while Global X Uranium ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Royalty Pharma plc Class A Ordinary Shares for 1 Days and Global X Uranium ETF for 62 Days on average.
| RPRX | URA | |
|---|---|---|
Market Cap | $25.27B | $5.48B |
Volume | 3,671,183 | 5,287,170 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $63.96 | $61.81 |
52-Week Low | $35.44 | $37.52 |
Typical Hold Time | 1 Days | 62 Days |
Enterprise Value | $32.50B | — |
Dividend Yield | 1.66% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
URA (Global X Uranium ETF) is trading at $38.96, down 2.43% today amid bearish technical signals. The ETF faces selling pressure with 19 sell signals versus 3 buy signals across technical indicators. Recent news highlights nuclear energy's growth potential from AI power demand and government support, though uranium ETFs have experienced volatility. The fund provides diversified exposure to uranium miners, utilities, and nuclear infrastructure companies.
The nuclear sector shows long-term potential driven by AI energy demands and government investments, but URA faces near-term technical headwinds. Key risks include commodity price volatility and concentrated holdings. Analyst sentiment remains mixed with some seeing value after recent declines while others caution about sector-specific challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Royalty Pharma plc Class A Ordinary Shares
Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →About Global X Uranium ETF
URA provides broad exposure to the global uranium industry and nuclear energy sector. Unlike pure-play mining funds, it includes companies involved in nuclear component production and infrastructure, with top 2026 holdings such as Cameco, Oklo, and Uranium Energy Corp.
Read more on URA →
